Carbon dioxide laser cordectomy for verrucous carcinoma of vocal folds

R HOD, R FEINMESSER, J SHVERO

Abstract

Background: Verrucous carcinoma occurs infrequently in the vocal folds. This tumour has an excellent prognosis with proper treatment. Management strategies include surgery, radiotherapy or both.

Aim: To evaluate the long-term results of type I and II laser cordectomy for the treatment of verrucous carcinoma of the vocal folds.

Materials and methods: We reviewed the files of 18 patients with verrucous carcinoma of the vocal folds treated by type I or II laser cordectomy in our department from 1989 to 2006, and recorded clinical and outcome data.

Results: None of the patients had any major post-operative complications. All had a subjectively satisfactory quality of voice, with no morbidity. Patient follow up ranged from three to 228 months (mean, 48 months). Five patients were treated with post-operative radiotherapy for persistent disease, of whom four underwent repeated surgery due to recurrence.

Conclusion: Type I or II laser cordectomy is a safe, feasible, secure method of treating verrucous carcinoma of the vocal folds. There were no major complications in our patient series. Most recurrent disease was manageable locally with repeated surgery.

Key words: Larynx Neoplasms; Verrucous Carcinoma; Laser; Vocal Cords

Introduction

Verrucous carcinoma is an uncommon variant of well differentiated squamous cell carcinoma which was first described by Ackerman in 1948.¹ It is primarily a disease of caucasian males older than 50 years. Verrucous carcinoma has a predilection for the mucous membranes of the head and neck, and is most commonly found in the oral cavity.² The second most common site is the larynx, where verrucous carcinoma has been reported only as a glottic or supra-glottic lesion.^{3,4} Currently, verrucous carcinoma accounts for 1 to 3.4 per cent of all laryngeal carcinomas.³

Although cigarette smoking is highly correlated with laryngeal lesions, it has not been identified as an aetiological or risk factor for verrucous carcinoma of the larynx.⁵ Alcohol consumption, however, has been shown to be correlated with this tumour.⁶

The diagnosis of vertucous carcinoma of the vocal folds is based on the following clinical and histopathological findings: a slow-growing, exophytic, grey, bulky lesion with a papillomatous appearance, which macroscopically comprises a broad-based and locally invasive tumour. Microscopically, the lesion is composed of highly differentiated squamous cells with acanthosis and hyperkeratosis, and large, blunt-ended rete ridges accompanied by an intact basement membrane.⁷ An inflammatory reaction consisting of lymphocytes and plasma cells is often present in the stroma. Verrucous carcinoma has a characteristic morphological appearance and specific clinical behaviour, and should be differentiated from other epidermoid carcinomas. Genetic studies have isolated human papillomavirus 16 related DNA sequences from verrucous carcinoma of the larynx.^{8,9}

Treatment strategies for this tumour include surgery, radiotherapy or both.^{10,11} Surgery has been associated with an 80 per cent local control rate and is usually the preferred first-line treatment modality.¹² The use of radiotherapy is still controversial. Many clinicians do not offer radiotherapy for primary management, because it has been shown in several studies to cause malignant transformation of verrucous carcinoma to undifferentiated carcinoma, and to place patients at risk of regional metastases.^{10,13–16} Other authors, however, have failed to find a direct relationship between radiotherapy and malignant transformation of verrucous carcinoma.¹⁷

Surgery procedures can be performed via an open approach, and include laryngofissure, supraglottic

From the Department of Otolaryngology–Head and Neck Surgery, Rabin Medical Center, Beilinson Campus, Petach-Tiqwa, Israel, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Israel. Accepted for publication: 12 June 2009. First published online 20 October 2009. laryngectomy, and total laryngectomy for transglottic lesions.¹⁰ Endoscopic carbon dioxide laser surgery has been found to be an effective alternative to such procedures. This technique was introduced in 1972 by Strong and Jako for the resection of nodules, polyps, cysts, carcinoma in situ and papillomatosis.¹⁸ Its advantages over open surgery include quicker recovery, less morbidity, fewer side effects and greater cost-effectiveness.^{19–22}

The European Laryngological Society has classified laser cordectomy into four types: subepithelial (type I), involving resection of the epithelium, and used for carcinoma in situ; subligamental (type II), involving resection of the epithelium, vocal ligament and Reinke's space, and used for tumour $(T)_{1a}$ lesions; transmuscular (type III), involving resection through the vocalis muscle; and total and extended (type IV), which encompasses the contralateral vocal fold and the anterior commissure.¹²

To date, most studies of verrucous carcinoma of the larynx have reported treatment with type III or IV cordectomy, or more radical procedures.^{23–25} However, although verrucous carcinoma is locally aggressive, it does not invade the basement membrane. Therefore, in our department, type I or II laser cordectomy is routinely used for treatment, without resection of the vocalis muscle, even when the lesion involves the anterior commissure or contralateral vocal fold.

The aim of this study was to evaluate the long-term results of type I and II laser cordectomy for the treatment of verrucous carcinoma of the vocal folds.

Materials and methods

The study group consisted of 18 patients with histopathologically proven verrucous carcinoma of the vocal folds who were treated at the Rabin Medical Center between 1989 and 2006. All patients had undergone videostroboscopy, which detected asymmetrical movement of the vocal folds and a slightly decreased mucosal wave of the involved vocal fold. Diagnosis had been made by direct microlaryngoscopy and biopsy under general anaesthesia, prior to surgery for evaluation of tumour extension or stage. All patients had been classified as having T_1 lesions of one or both vocal folds, without subglottic extension or involvement of the anterior commissure and/or arytenoids. Only those who had undergone first-line type I or II microlaryngoscopy with carbon dioxide laser were included. Patients' files were reviewed for clinical and outcome data.

Surgical technique

After induction of general anaesthesia by transoral intubation (using a latex Woodbridge tracheal tube), a rigid laryngoscope (an 18 cm, distending operating laryngoscope; Storz, Weerda, Germany) was introduced through the mouth. Adequate endoscopic visualisation of the larynx was ensured by widening the laryngoscope's spatulas, and by using a 0° Hopkins II endoscope (5 mm diameter, 24 mm length; Storz) to evaluate tumour extension (subglottically and in the sinus Morgagni). All safety

precautions were applied. Adrenaline 0.3 cm^3 together with saline 9 cm^3 was injected laterally to the tumour, between the vocalis muscle and the vocal ligament, in two different sites (anterior and posterior). A carbon dioxide laser beam (SmartXide 8 W system in super-pulse mode with spot size $0.6-0.8 \text{ mm}^2$; Deka, Firenze, Italy) coupled via a micromanipulator to a Zeiss microscope (Opmi 6; Zeiss, Thornwood, New York, USA) was used. The lesion was excised en bloc if possible, or piecemeal, with a safe margin of healthy tissue. The completeness of the excision was ensured by inserting and controlling the operating field with the same 0° endoscope.

After tumour excision, intra-operative frozen sections were taken from the excision margins (anteriorly, posteriorly, inferiorly and laterally). The tumour was always removed with an adequate margin of healthy tissue, well visualised through the microscope.

One patient who had initially been seen at another hospital presented with a large glottic mass which necessitated a laryngofissure. In this case, laser cordectomy (type II) was performed through the laryngofissure.

Post-operatively, patients were advised to resume their normal diet on the first day. They were invited for follow-up examination, commencing three weeks after the cordectomy procedure and continuing every month thereafter. After three months, a 'second-look' operation was performed to collect multiple biopsy samples, to monitor vocal fold status.

Results

The study group consisted of 14 men and four women, aged 36 to 82 years (mean age 58 years). All patients had T_1 lesions. Their clinical data are shown in Table I.

A documented history of smoking was recorded for 15 patients, and of alcohol intake for two; one had a history of voice abuse. There were no data on signs of reflux for any of the patients. The right vocal fold was affected in 12 patients, the left in four and both in two.

Hoarseness was the most prevalent presenting symptom (occurring in all patients). Three patients had dyspnoea, and one patient complained of throat pain.

None of the patients had a neck lesion on presentation.

Follow up ranged from three to 228 months (mean, 48 months). Thirteen patients had no evidence of recurrent disease throughout follow up (Figure 1). The remaining five patients had persistent disease after cordectomy and therefore underwent radiotherapy. Two of these patients had histological evidence of squamous cell carcinoma in addition to verrucous carcinoma of the larynx. The other three had multiple recurrences involving both vocal folds and the anterior commissure. Four of the patients with primary cordectomy failure underwent repeated cordectomy (two required several surgical procedures). In no case was chemotherapy administered as second-line treatment.

Pt no	Sex	Presenting age (y)	Smoking?	Tumour site	Surgery	Tumour stage	Complications	Completion Rx?	Outcome
1	F	82	No	R	Laser	T_1			
2	F	58	Yes	Bilat	Laser	T_1			
3	Μ	73	Yes	L	Laser	T_1			
4	Μ	46	Yes	R	Laser	T_1			
5	Μ	60	Yes	R	Laser	T_1		Yes	Recurrence
6	Μ	53	Yes	R	Laser	T_1			
7	Μ	59	Yes	L	Laser	T_1			Recurrence
8	F	53	No	R	Laser	T_1			
9	Μ	49	Yes	R	Laser	T_1			
10	М	46	Yes	Bilat	Laryngofissure + laser	T_1		Yes	
11	Μ	63	Yes	R	Laser	T_1			
12	Μ	58	Yes	R	Laser	T_1			
13	М	81	Yes	L	Laser	T_1^1	Vocal fold oedema	Yes	Recurrence
14	М	55	Yes	L	Laser	T_1		Yes	Recurrence
15	Μ	55	Yes	R	Laser	T_1			
16	Μ	39	Yes	R	Laser	T_1			
17	F	58	Yes	R	Laser	T_1			
18	М	50	No	R	Laser	T_1		Yes	Recurrence

 TABLE I

 CLINICAL DATA FOR 18 PATIENTS WITH VERRUCOUS CARCINOMA OF VOCAL FOLDS

Pt no = patient number; y = years; completion Rx = completion radiotherapy; F = female; M = male; R = right; L = left; bilat = bilateral; T = tumour



Fig. 1



None of the patients suffered any of the reported complications of laser cordectomy, such as dysphagia, aspiration or glottic-supraglottic stenosis.²⁶ Laryngeal oedema developed in one patient and was treated medically with good results.

All patients were alive and well after the minimum follow-up period of three months. No patient died of their disease.

Discussion

The benefits of carbon dioxide laser excision are well known: precise application; minimal tissue damage and surgical trauma; almost bloodless resection; and rapid tissue healing. In cases of laryngeal verrucous carcinoma, this technology has several advantages over standard therapy, including less morbidity, fewer side effects, shorter hospital stay and greater cost-effectiveness. Its disadvantages include problems manoeuvring the endoscope in patients with a short neck or cervical pathology, and the risk that the surgeon will not be able to visualise the anterior commissure and that surgery will therefore not be as radical as it should be (in such cases we suggest piecemeal tumour removal). All our patients underwent a second look operation after three months.

To the best of our knowledge, this report describes the largest series of patients with verrucous carcinoma of the vocal folds treated by type I or II laser cordectomy. Other studies have described more extensive procedures, such as cordectomy beyond the vocalis muscle (i.e. type III or IV), or partial or total laryngectomy.²³

- Verrucous carcinoma occurs infrequently in the vocal folds
- This tumour has an excellent prognosis with proper treatment; management strategies include surgery, radiotherapy or both
- This study assessed the use of CO₂ laser cordectomy in treating 18 patients with verrucous carcinoma of the vocal folds
- Type I or II laser cordectomy is a safe, feasible and secure method of treating this tumour
- Most recurrent disease can be managed locally with repeated surgery

In type I or II laser cordectomy, the mucosa of the vocal folds is resected, leaving the vocal muscle

intact. Therefore, morbidity is lower, the subjective vocal quality is better, and there are fewer complications in terms of local oedema or impaired vocal fold mobility. In our series, the only complication was mild laryngeal oedema, which resolved after local treatment. The majority of our patients (72 per cent) had a good outcome, including satisfactory objective voice quality, and needed no further treatment. Only five patients required adjunctive radiotherapy, to control multiple recurrence of the disease in three patients and concomitant squamous cell carcinoma in two. Four of these five patients underwent repeated laser cordectomy.

Conclusion

Overall, our findings indicate that type I or II laser cordectomy is a feasible and safe procedure for the treatment of selected patients with verrucous carcinoma of the larynx. Prerequisites include a normal neck and the absence of subglottic extension, stridor or extensive lesions. Repeated laser cordectomy is also appropriate in cases of recurrence. We suggest that radiotherapy be reserved for severe cases of multiple recurrence, persistent disease or concomitant squamous cell carcinoma. In patients with a short neck or anterior commissure involvement, we suggest a laryngofissure procedure followed by laser cordectomy. Larger, multicentre studies are needed to confirm these findings and to standardise an appropriate approach to the treatment of laryngeal verrucous carcinoma.

References

- 1 Ackerman LV. Verrucous carcinoma of the oral cavity. *Surgery* 1948;**23**:670-8
- 2 McDonald JS, Crissman JD, Gluckman JL. Verrucous carcinoma of the oral cavity. *Head Neck Surg* 1982;5:22–8
- 3 Lee RJ. Verrucous carcinoma of the larynx. *Otolaryngol Head Neck Surg* 1988;98:593-5
 4 Koch BB, Trask DK, Hoffman HT. National survey of
- 4 Koch BB, Trask DK, Hoffman HT. National survey of head and neck verrucous carcinoma. *Cancer* 2001;**92**: 110–20
- 5 Spiro R. Verrucous carcinoma: then and now. *Am J Surg* 1998;**171**;393–7
- 6 Oliveira DT, de Moraes RV, Filho JFF. Oral verrucous carcinoma: a retrospective study in Sao Paulo region, Brazil. *Clin Oral Invest* 2006;**10**:205–9
- 7 Ferlito A. Atypical forms of squamous cell carcinoma. In: Michaels L, ed. *Pathology of the Larynx*. Berlin: Springer, 1984;135–59
- 8 Brandsma JL, Steinberg BM, Abramson AL, Winkler B. Presence of human papillomavirus type 16 related sequences in verrucous carcinoma of the larynx. *Cancer* 1986;46:2185-8
- 9 Dekmezian RH, Batsakis JG, Goepfert H. In situ hybridization of papillomavirus DNA in head and neck squamous cell carcinomas. Arch Otolaryngol Head Neck Surg 1987; 113:819–21
- 10 Hagen P, Lyons GD, Haindel C. Verrucous carcinoma of the larynx: role of HPV, radiation and surgery. *Laryngo-scope* 1993;103;253–7

- 11 Burns HP, Van Nostrand AWP, Bryce DP. Verrucous carcinoma of the larynx. Management by radiotherapy and surgery. *Ann Otol Rhinol Laryngol* 1976;**85**:538–43
- 12 Remacle M, Eckel HE. Endoscopic cordectomy. A proposal for a classification by the working committee, European Laryngological Society. *Eur Arch Otorhinolaryngol* 2000; 257:227–31
- 13 Tharp ME, Shidnia H. Radiotherapy in the treatment of verrucous carcinoma of the head and neck. *Laryngoscope* 1995;**105**:391–6
- 14 Perez CA, Kraus FT, Evans JC, Powers WE. Anaplastic transformation in verrucous carcinoma of the oral cavity after radiation therapy. *Radiology* 1966;86:108–15
 15 Smith RRL, Kuhadja FP, Harris RE. Anaplastic trans-
- 15 Smith RRL, Kuhadja FP, Harris RE. Anaplastic transformation of verrucous carcinoma following radiotherapy. *Am J Otolaryngol* 1985;6:448–52
- 16 Edstrom S, Johansson SL, Lindstrom J, Sandin I. Verrucous squamous cell carcinoma of the larynx: evidence for increased metastatic potential after irradiation. *Arch Otolaryngol Head Neck Surg* 1987;97:381–4
 17 O'Sullivan B, Warde P, Keane T, Irish J, Cummings B,
- 17 O'Sullivan B, Warde P, Keane T, Irish J, Cummings B, Payne D. Outcome following radiotherapy in verrucous carcinoma of the larynx. *Int J Radiat Oncol Biol Phys* 1995;**32**:611–17
- 18 Strong MS, Jako GJ. Laser surgery in the larynx. Early clinical experience with continuous CO₂ laser. Ann Otol Rhinol Laryngol 1972;81;791–8
- 19 Casiano RR, Cooper JD, Lundy DS, Chandler JR. Laser cordectomy for T1 glottic carcinoma: a 10 year experience and videostroboscopic findings. *Otolaryngol Head Neck* Surg 1991;**104**:831–7
- Peretti G, Nicolai P, Piazza C, Redaelli de Zinis LO, Valentini S, Antonelli AR. Oncological results of endoscopic resections of TIS and T1 glottic carcinomas by CO₂ laser. Ann Otol Laryngol 2001;100:820-6
 Remacle M, Lawson G. Transoral laser microsurgery is
- Remacle M, Lawson G. Transoral laser microsurgery is the recommended treatment for early glottic cancers. *Acta Otorhinolaryngol Belg* 1999;53:175–8
 Shvero J, Koren R, Stern Y, Segal K, Feinmesser R, Hadar
- 22 Shvero J, Koren R, Stern Y, Segal K, Feinmesser R, Hadar T. Laser surgery for the treatment of glottic carcinomas. *Am J Otol* 2003;24:28–33
- 23 Damm M, Eckel HE, Schneider D, Arnold G. CO₂ laser surgery for verrucous carcinoma of the larynx. *Lasers* Surg Med 1997;21:117-23
- 24 Lundgren JA, Van Nostrand AW, Harwood AR, Cullen RJ, Bryce DP. Verrucous carcinoma of the larynx: diagnostic and therapeutic considerations. *Head Neck Surg* 1986;9: 19–26
- 25 McCaffrey T, Witte M, Ferguson M. Verrucous carcinoma of the larynx. Ann Otol Rhinol Laryngol 1998; 107:391–5
- 26 Ellies M, Steiner W. Peri- and postoperative complications after laser surgery of tumors of the upper aerodigestive tract. *Am J Otolaryngol* 2007;**28**:168–72

Address for correspondence: Dr Roy Hod, Department of Otolaryngology–Head and Neck Surgery, Rabin Medical Center, Beilinson Campus, Petach Tikva 49100, Israel.

Fax: +972 3 937 6467 E-mail: royhod2@clalit.org.il

Dr R Hod takes responsibility for the integrity of the content of the paper. Competing interests: None declared